Physician profile
Amy Su
NPI 1255315776
$9,915.99
in general payments reported to CMS, 2019-2025
28 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,585 · 2020: $300 · 2021: $1,225 · 2022: $63.60 · 2023: $1,048 · 2024: $1,463 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,680 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.38 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,598.79 | 2019-2025 | |
| Abbvie INC. | $625.78 | 2019-2025 | Linzess, Viberzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $615.18 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $499.19 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $398.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $369.26 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Novo Nordisk INC | $294.08 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $207.96 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $198.31 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $171.95 | 2019-2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.64 | 2020-2025 | Xifaxan |
| Pfizer INC. | $104.13 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $70.90 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $70.36 | 2022-2023 | Nexletol |
| Akebia Therapeutics INC | $69.28 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $62.56 | 2019-2024 | Veozah |
| Seqirus USA INC | $61.97 | 2021 | |
| Smith+Nephew, INC. | $58.68 | 2024-2025 | Collagenase Santyl |
| Exact Sciences Corporation | $57.24 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $49.56 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $36.21 | 2024-2025 | Zoryve |
| Allergan, INC. | $28.27 | 2019 | |
| Intra-Sana Laboratories | $25.57 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Shield Therapeutics INC | $23.16 | 2023 | Accrufer |
| Boston Scientific Corporation | $20.37 | 2019 | |
| Calliditas Therapeutics US INC. | $20.05 | 2023 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $19.55 | 2019 | |
| Eisai INC. | $18.85 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.